Measurement of Relaxin Peptide in Multiple Sclerosis (MS)
Measurement of Relaxin in the Serum and Cerebrospinal Fluid of Subjects With and Without the Relapsing Form of Multiple Sclerosis
Sponsor: Microstein, LLC
A observational or N/A phase clinical study on Multiple Sclerosis, Relapsing-Remitting, this trial is completed. The trial is conducted by Microstein, LLC and has accumulated 17 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
17 versions recorded-
Jul 2025 — Present [monthly]
Completed
-
Sep 2024 — Jul 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2023 — Jul 2024 [monthly]
Completed
Status: Recruiting → Completed
-
Jul 2023 — Dec 2023 [monthly]
Recruiting
▶ Show 12 earlier versions
-
Mar 2022 — Jul 2023 [monthly]
Recruiting
-
Feb 2022 — Mar 2022 [monthly]
Recruiting
-
Dec 2021 — Feb 2022 [monthly]
Recruiting
-
Jan 2021 — Dec 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Recruiting
-
Nov 2018 — Oct 2020 [monthly]
Recruiting
-
Jun 2018 — Nov 2018 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Sep 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Microstein, LLC
- Providence Health & Services
For direct contact, visit the study record on ClinicalTrials.gov .